Pre-clinical evaluation of a CEA DNA prime/protein boost vaccination strategy against colorectal cancer

Scandinavian Journal of Immunology

Volumn 66, Issue 1, 2007, Pages 43-51

  Hallermalm, K ^a,b   Johansson, S ^b   Brave A ^b   Ek, M ^b   Engstrom G ^b   Boberg, A ^b   Gudmundsdotter, L ^b   Blomberg, P ^c   Mellstedt, H ^c   Stout, R ^d   Liu, M A ^e   Wahren, B ^b  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Bioject Medical Technologies   (United States)

^e ProTherImmune   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN 66 PLUS DNA VACCINE; RECOMBINANT CARCINOEMBRYONIC ANTIGEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHEMOPROPHYLAXIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG POTENTIATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; JET INJECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; T LYMPHOCYTE ACTIVATION;

5'-GUANYLIC ACID; ADJUVANTS, IMMUNOLOGIC; ANIMALS; BLOTTING, WESTERN; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HELA CELLS; HUMANS; INJECTIONS, JET; MICE; PLASMIDS; T-LYMPHOCYTES; TRANSFECTION; TRANSGENES; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 34250721613     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2007.01945.x     Document Type: Article

References (38)

1. Huang EH, Kaufman HL. CEA-based vaccines. Expert Rev Vaccines 2002 1 : 49 63.
2. Samanci A, Yi Q, Fagerberg J et al. Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. Cancer Immunol Immunother 1998 47 : 131 42.
3. Horig H, Lee DS, Conkright W et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 2000 49 : 504 14.
4. Marshall JL, Hoyer RJ, Toomey MA et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000 18 : 3964 73.
5. Fong L, Hou Y, Rivas A et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 2001 98 : 8809 14.
6. Mosolits S, Ullenhag G, Mellstedt H. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann Oncol 2005 16 : 847 62.
7. Ullenhag GJ, Frodin JE, Jeddi-Tehrani M et al. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin Cancer Res 2004 10 : 3273 81.
8. Barnett SW, Rajasekar S, Legg H et al. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine 1997 15 : 869 73.
9. Irvine KR, Chamberlain RS, Shulman EP, Surman DR, Rosenberg SA, Restifo NP. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J Natl Cancer Inst 1997 89 : 1595 601.
10. Lund LH, Andersson K, Zuber B et al. Signal sequence deletion and fusion to tetanus toxoid epitope augment antitumor immune responses to a human carcinoembryonic antigen (CEA) plasmid DNA vaccine in a murine test system. Cancer Gene Ther 2003 10 : 365 76.
11. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999 9 : 67 81.
12. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. Syfpeithi: database for MHC ligands and peptide motifs. Immunogenetics 1999 50 : 213 9.
13. Zhang GL, Srinivasan KN, Veeramani A, August JT, Brusic V. Predbalb/c: a system for the prediction of peptide binding to H2d molecules, a haplotype of the BALB/c mouse. Nucleic Acids Res 2005 33 : W180 3.
14. OECD Standard OfECaD. Principles of good laboratory practice (GLP). 1997.
15. Brave A, Ljungberg K, Boberg A et al. Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol Ther 2005 12 : 1197 205.
16. Sandström E, Wahren B, Hejdeman B et al. Multigene, multiclade HIV-1 plasmid DNA prime and MVA boost is safe and highly immunogenic in healthy human volunteers. Antivir Ther 2006 11 : 03 2.
17. Sheets RL, Stein J, Manetz TS et al. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, severe acute respiratory syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicol Sci 2006 91 : 610 9.
18. Chang DZ, Lomazow W, Joy Somberg C, Stan R, Perales MA. Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines. Hematology 2004 9 : 207 15.
19. Hedin A, Zoubir F, Lundgren T, Hammarstrom S. Epitope specificity and cross-reactivity pattern of a large series of monoclonal antibodies to carcinoembryonic antigen. Mol Immunol 1986 23 : 1053 61.
20. Drew DR, Lightowlers M, Strugnell RA. Humoral immune responses to DNA vaccines expressing secreted, membrane bound and non-secreted forms of the Tania ovis 45W antigen. Vaccine 2000 18 : 2522 32.
21. Lewis PJ, van Drunen Littel-van den H, Babiuk LA. Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response. J Virol 1999 73 : 10214 23.
22. Morel PA, Falkner D, Plowey J, Larregina AT, Falo LD. DNA immunisation: altering the cellular localisation of expressed protein and the immunisation route allows manipulation of the immune response. Vaccine 2004 22 : 447 56.
23. Kowalczyk DW, Wlazlo AP, Giles-Davis W, Kammer AR, Mukhopadhyay S, Ertl HC. Vaccine-induced CD8+ T cells eliminate tumors by a two-staged attack. Cancer Gene Ther 2003 10 : 870 8.
24. Qin Z, Schwartzkopff J, Pradera F et al. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 2003 63 : 4095 100.
25. Shankaran V, Ikeda H, Bruce AT et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001 410 : 1107 11.
26. Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001 97 : 192 7.
27. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002 2 : 735 47.
28. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions J Leukoc Biol 2004 75 : 163 89.
29. Tannenbaum CS, Hamilton TA. Immune-inflammatory mechanisms in IFNgamma-mediated anti-tumor activity. Semin Cancer Biol 2000 10 : 113 23.
30. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994 1 : 447 56.
31. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998 188 : 2357 68.
32. Prevost-Blondel A, Neuenhahn M, Rawiel M, Pircher H. Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen. Eur J Immunol 2000 30 : 2507 15.
33. Keene JA, Forman J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med 1982 155 : 768 82.
34. Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 1997 186 : 65 70.
35. Ostrand-Rosenberg S. CD4+ T lymphocytes: a critical component of antitumor immunity. Cancer Invest 2005 23 : 413 9.
36. Letvin NL, Montefiori DC, Yasutomi Y et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci U S A 1997 94 : 9378 83.
37. McConkey SJ, Reece WH, Moorthy VS et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003 9 : 729 35.
38. Wang R, Epstein J, Charoenvit Y et al. Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein. J Immunol 2004 172 : 5561 9.